UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 592

Sortiert nach

Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practice

Cancer treatment reviews, 2012-08, Vol.38 (5), p.397-406

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

The New England journal of medicine, 2015-05, Vol.372 (20), p.1909-1919

2015

Link zum Volltext

Verfügbarkeit prüfen

Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays

PloS one, 2012-10, Vol.7 (10), p.e46536-e46536

2012

Link zum Volltext

Verfügbarkeit prüfen

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

The lancet oncology, 2014-05, Vol.15 (6), p.569-579

2014

Link zum Volltext

Verfügbarkeit prüfen

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

Journal of clinical oncology, 2013-02, Vol.31 (6), p.759-765

2013

Link zum Volltext

Verfügbarkeit prüfen

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor

Expert opinion on investigational drugs, 2015-11, Vol.24 (11), p.1493-1500

2015

Link zum Volltext

Verfügbarkeit prüfen

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

The Lancet (British edition), 2011-12, Vol.378 (9808), p.2005-2012

2011

Link zum Volltext

Verfügbarkeit prüfen

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1626-1634

2008

Link zum Volltext

Verfügbarkeit prüfen

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

Clinical cancer research, 2013-04, Vol.19 (7), p.1902-1912

2013

Link zum Volltext

Verfügbarkeit prüfen

Multisciplinary management of patients with liver metastasis from colorectal cancer

World journal of gastroenterology : WJG, 2016-08, Vol.22 (32), p.7215-7225

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2010-11, Vol.28 (31), p.4706-4713

2010

Link zum Volltext

Verfügbarkeit prüfen

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Journal of clinical oncology, 2007-05, Vol.25 (13), p.1658-1664

2007

Link zum Volltext

Verfügbarkeit prüfen

The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies

Frontiers in immunology, 2021-09, Vol.12, p.737311-737311

2021

Link zum Volltext

Verfügbarkeit prüfen

Cellular senescence in cancer: clinical detection and prognostic implications

Journal of experimental & clinical cancer research, 2022-12, Vol.41 (1), p.360-360, Article 360

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy

Journal of clinical oncology, 2010-08, Vol.28 (23), p.3687-3694

2010

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Magnetic Resonance Imaging and Histopathological Response to Chemoradiotherapy in Locally Advanced Rectal Cancer

Annals of surgical oncology, 2012-09, Vol.19 (9), p.2842-2852

2012

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study

Journal of clinical oncology, 2010-10, Vol.28 (29), p.4450-4456

2010

Link zum Volltext

Verfügbarkeit prüfen

Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice

Oncotarget, 2016-05, Vol.7 (19), p.28748-28760

2016

Link zum Volltext

Verfügbarkeit prüfen

Anti‐Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance

The oncologist (Dayton, Ohio), 2013-07, Vol.18 (7), p.850-864

2013

Link zum Volltext

Verfügbarkeit prüfen

HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques

PloS one, 2019-09, Vol.14 (9), p.e0220906-e0220906

2019

Link zum Volltext

Verfügbarkeit prüfen

Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer

European journal of cancer (1990), 2016-11, Vol.68, p.51-59

2016

Link zum Volltext

Verfügbarkeit prüfen

Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

Journal of clinical oncology, 2009-10, Vol.27 (30), p.5068-5074

2009

Link zum Volltext

Verfügbarkeit prüfen

Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1

Journal of molecular endocrinology, 2015-04, Vol.54 (2), p.137-147

2015

Link zum Volltext

Verfügbarkeit prüfen

Large-scale analysis of DFNA5 methylation reveals its potential as biomarker for breast cancer

Clinical epigenetics, 2018-04, Vol.10 (1), p.51-51, Article 51

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option

International journal of molecular sciences, 2017-02, Vol.18 (2), p.418-418

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 592

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(567)
Mit Volltextzugriff
(505)

Publikationsform

Artikel
(592)

Sprache

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(592)
Ingenta
(290)
Free E-Journal (出版社公開部分のみ）
(289)
Ovid Journals
(263)
IngentaConnect Journals
(165)
NUS Single-Journal Subscriptions
(161)
Elsevier ScienceDirect Journals Complete
(122)
SpringerLink
(109)
Wiley Online Library
(77)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(60)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(51)
Wiley Online Library Full Collection 2018
(51)
SAGE Journals
(40)
Oxford Journals
(38)
Oxford Journals 2020 Medicine
(36)
Taylor & Francis
(21)
Nature Journals
(20)
Taylor & Francis Online
(12)
JSTOR
(11)
Nexis
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practice

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

Multisciplinary management of patients with liver metastasis from colorectal cancer

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies

Cellular senescence in cancer: clinical detection and prognostic implications

Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy

Comparison of Magnetic Resonance Imaging and Histopathological Response to Chemoradiotherapy in Locally Advanced Rectal Cancer

Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study

Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice

Anti‐Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance

HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques

Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer

Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1

Large-scale analysis of DFNA5 methylation reveals its potential as biomarker for breast cancer

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option

Aktive Filter

Suchergebnisse filtern